医学
1型糖尿病
疾病
免疫系统
重症监护医学
临床试验
阶段(地层学)
临床终点
糖尿病
干预(咨询)
免疫
叙述性评论
随机对照试验
机会之窗
免疫学
内科学
微小残留病
2型糖尿病
匹配(统计)
获得性免疫系统
免疫病理学
生物信息学
肿瘤科
自身免疫性疾病
复杂疾病
机制(生物学)
免疫抑制
临床意义
作者
Chenming Ye,Zhenning Jin,Shen S. Hu
摘要
AIMS: To propose a stage-adapted framework for disease-modifying therapy in type 1 diabetes (T1D) that integrates immune plasticity and residual β-cell function, and to examine how these evolving constraints may inform treatment selection, combination strategies, and trial endpoints. MATERIALS AND METHODS: This narrative review synthesizes mechanistic, observational, and interventional evidence across presymptomatic T1D, recent-onset Stage 3 disease, and longer-duration Stage 3 disease. Evidence relating to immune modulation, antigen-specific intervention, β-cell protection, and β-cell replacement was interpreted according to disease stage and biological context. RESULTS: Available evidence suggests that therapeutic responsiveness is shaped by two co-evolving constraints: immune plasticity and residual β-cell function. Early disease may provide a window in which autoreactive immunity can still be redirected and endogenous β-cell function preserved. In established disease, stabilized immune memory, reduced regulatory capacity, and substantial β-cell loss increasingly limit the effects of immune-directed intervention alone. Accordingly, immune-tolerance and β-cell-preservation strategies may have greater potential earlier in the disease course, whereas established disease may require β-cell replacement combined with graft protection and metabolic management. CONCLUSIONS: Stage-adapted treatment matching provides a clinically interpretable framework rather than a validated treatment algorithm. Integrating disease stage with immune endotype, residual β-cell function, treatment feasibility, and stage-appropriate endpoints may improve the design and interpretation of disease-modifying trials and warrants prospective validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI